Anti-tumor effect of Merocyanine 540-mediated photochemotherapy combined with Edelfosine: potential implications for the ex vivo purging of hematopoietic stem cell grafts from breast cancer patients

Andérson, Gregory S.; Miyagi, Kiyoko; Sampson, Reynée W.; Sieber, Fritz

doi:10.1016/s1011-1344(02)00377-9

Cited by 22 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the potentiating effect of Edelfosine on the photoinactivation of normal bone marrow cells was small compared to that of leukemia cells. Siebe and co-workers [64,65] performed an initial assessment of the safety and efficacy of a simi-lar two-step purging procedure (MC540-PDT followed by edelfosine). A variety of cell lines, moderately to minimally sensitive to MC540-PDT, were employed.…”

Section: Pdt and Chemotherapymentioning

confidence: 99%

Combination of Photodynamic Therapy with Anti-Cancer Agents

Mf¹,

Lange

2008

CMC

154

131

View full text Add to dashboard Cite

Degenerative diseases such as cancer usually involve more than one pathological process. Therefore, attempts to combat such diseases with monotherapeutic approaches may not always do so efficiently. For this reason, the use of combination therapy with modalities that target different disease pathways represents an alternative strategy. Photodynamic therapy (PDT) has already been established as an alternative therapy for the treatment of various types of malignant disorders, including oesophageal, lung and bladder cancer as well as other degenerative diseases. This technique involves the administration of a tumor localizing photosensitizer followed by its activation with light of a specific wavelength. In the presence of tissue oxygen, the photoactive sensitizer triggers a series of photochemical and photobiological processes that may lead to direct cancer cell damage, tumor microvascular occlusion and host immune response. Due to these multiple actions, PDT has increasingly gained recognition as a potential adjuvant for conventional cancer treatments. Several preclinical studies and some clinical trials suggest that the use of PDT in combination with established treatments or with newly-developed modalities may be of benefit as compared to the individual modalities. In this review, we briefly introduce the reader to the main photobiological aspects of PDT, and then discuss the use of PDT in combination with other pharmacological approaches for the treatment of cancer.

show abstract

Section: Pdt and Chemotherapymentioning

confidence: 99%

Combination of Photodynamic Therapy with Anti-Cancer Agents

Mf¹,

Lange

2008

CMC

154

131

View full text Add to dashboard Cite

show abstract

“…Importantly, MC540‐PDT is well tolerated by normal hematopoietic stem and progenitor cells with a significant percentage of granulocyte macrophage colony‐forming units and erythroid burst‐forming units remaining preserved (203). However, efficacy appears to be limited in the treatment of solid tumor cells (204).…”

mentioning

confidence: 99%

Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy

O’Connor

Gallagher

Byrne

2009

Photochem & Photobiology

1,082

789

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is now a well-recognized modality for the treatment of cancer. While PDT has developed progressively over the last century, great advances have been observed in the field in recent years. The concept of dual selectivity of PDT agents is now widely accepted due to the relative specificity and selectivity of PDT along with the absence of harmful side effects often encountered with chemotherapy or radiotherapy. Traditionally, porphyrin-based photosensitizers have dominated the PDT field but these first generation photosensitizers have several disadvantages, with poor light absorption and cutaneous photosensitivity being the predominant side effects. As a result, the requirement for new photosensitizers, including second generation porphyrins and porphyrin derivatives as well as third generation photosensitizers has arisen, with the aim of alleviating the problems encountered with first generation porphyrins and improving the efficacy of PDT. The investigation of nonporphyrin photosensitizers for the development of novel PDT agents has been considerably less extensive than porphyrin-based compounds; however, structural modification of nonporphyrin photosensitizers has allowed for manipulation of the photochemotherapeutic properties. The aim of this review is to provide an insight into PDT photosensitizers clinically approved for application in oncology, as well as those which show significant potential in ongoing preclinical studies.

show abstract

“…[7][8][9][10][11][12][13][14][15][16] Small cell lung, [17][18][19] prostate 19 and breast tumor [19][20][21] cells were mostly analyzed from solid cancers. To mimic in vivo conditions, artificial cell mixture models have been used by several investigators.…”

Section: Introductionmentioning

confidence: 99%

Hexaminolevulinate-mediated photodynamic purging of leukemia cells from BM

Čunderlı́ková

Vasovič

Sieber

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

Photodynamic therapy (PDT) with porphyrin precursors has been established for tumor treatment. This study aimed at examining applicability of hexaminolevulinate (HAL) for photodynamic purging of leukemic cells from BM grafts and evaluating the clinical relevance of in vitro models. The PDT dose resulting in no colony formation by leukemic cells in vitro, in pure form or in a mixture with BM cells, was insufficient for complete killing of the leukemic cells ex vivo and for the treatment of the leukemia-bearing animals in vivo. The efficacy of HAL-PDT in cell lines in vitro should be verified in clinically relevant in vivo models.

show abstract

Anti-tumor effect of Merocyanine 540-mediated photochemotherapy combined with Edelfosine: potential implications for the ex vivo purging of hematopoietic stem cell grafts from breast cancer patients

Cited by 22 publications

References 32 publications

Combination of Photodynamic Therapy with Anti-Cancer Agents

Combination of Photodynamic Therapy with Anti-Cancer Agents

Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy

Hexaminolevulinate-mediated photodynamic purging of leukemia cells from BM

Contact Info

Product

Resources

About